Breast Cancer History at a Glance

• About 1600 BCE: An Egyptian medical text describes breast tumors.
• Fifth century BCE: Hippocrates connects cancer with the humoral theory of disease.
• Second century CE: Galen expands the idea that “black bile” causes tumors.
• 1700s: Physicians begin describing cancer as a disease that can spread through lymphatic pathways.
• 1894: William Halsted publishes results for the radical mastectomy.
• 1895: George Beatson reports that removing the ovaries can slow some breast cancers.
• 1913: Albert Salomon uses X-rays to examine thousands of breast specimens.
• 1960s–1980s: Clinical trials challenge radical surgery and establish breast-conserving treatment.
• 1977: Tamoxifen receives U.S. approval for breast cancer treatment.
• 1994–1995: BRCA1 and BRCA2 are identified.
• 1998: Trastuzumab is approved for HER2-positive metastatic breast cancer.
• 2015 onward: CDK4/6 inhibitors reshape treatment for advanced hormone receptor-positive disease.
• 2020s: Immunotherapy and antibody-drug conjugates expand treatment options for several breast cancer subtypes.

Ancient Breast Cancer: The First Written Evidence

About 1600 BCE: The Edwin Smith Papyrus

The earliest widely recognized written descriptions of breast tumors appear in the Edwin Smith Papyrus, an Egyptian medical document copied around 1600 BCE from material that may have been considerably older. It describes several cases involving hard, bulging masses of the breast. The writer distinguished these tumors from infections and other injuries but offered a grim assessment: there was no effective treatment.

This ancient account is remarkable because it relies on physical observation rather than magic alone. The examiner noted the tumors’ texture, temperature, and boundaries. Unfortunately, diagnosis was far ahead of therapy. Physicians could recognize something dangerous, but they had no anesthesia, pathology laboratory, imaging equipment, or reliable way to stop cancer after it spread.

Fifth Century BCE: Hippocrates and the Crab

Hippocrates and physicians associated with his school used the Greek terms karkinos and karkinoma for certain tumors. The words referred to a crab, possibly because swollen veins extending from a tumor resembled legs spreading from a shell.

Hippocratic medicine explained illness through four bodily fluids, or humors. Cancer was associated with an excess of black bile. This theory was incorrect, but it dominated medical thinking for centuries. Since the supposed cause circulated throughout the body, surgery was often considered useless or potentially harmful. That conclusion accidentally discouraged some dangerous operations, although it also delayed useful experimentation.

Second Century CE: Galen Strengthens the Humoral Theory

The influential Roman physician Galen expanded the black-bile explanation and classified breast tumors according to their appearance and behavior. His writings shaped European and Middle Eastern medicine for more than a thousand years. When one physician’s theory remains popular for that long, peer review is clearly moving at the speed of a sleepy tortoise.

Galen sometimes supported surgery for limited tumors, but deeply rooted cancers were generally considered incurable. Without knowledge of cells, hormones, DNA, or metastasis, physicians could describe what they saw but could not explain the underlying disease.

From the Renaissance to the Age of Surgery

1500s–1700s: Anatomy Begins Replacing Ancient Theory

Renaissance anatomy gradually weakened the humoral model. Physicians performing dissections could not locate the mysterious reservoirs of black bile that supposedly produced cancer. Researchers proposed alternative explanations involving blocked ducts, damaged glands, inflammation, trauma, and the lymphatic system.

In the eighteenth century, French surgeon Henri François Le Dran argued that breast cancer began locally and then spread through lymphatic channels to nearby nodes. This idea encouraged surgeons to remove the breast together with regional lymphatic tissue. It was an important step toward understanding metastasis, although later surgeons would take the “remove everything nearby” concept much further than necessary.

1800s: Anesthesia, Antisepsis, and Bigger Operations

Two nineteenth-century developments transformed surgery: anesthesia made longer procedures possible, and antiseptic methods reduced the likelihood of fatal infection. Surgeons could now attempt operations that earlier patients could not have survived.

These advances created an unfortunate side effect: because more extensive surgery was technically possible, doctors often assumed it must be more effective. Breast operations expanded from removing a lump to removing the entire breast, chest muscles, underarm lymph nodes, and surrounding tissues. The operating room had gained better tools, but the theory guiding those tools was still incomplete.

1894: Halsted’s Radical Mastectomy

Johns Hopkins surgeon William Stewart Halsted developed and promoted the radical mastectomy. His operation removed the breast, both pectoral muscles, and extensive axillary lymph nodes in one block of tissue. In 1894, he published outcomes that appeared better than those achieved by many earlier, less standardized procedures.

Halsted believed breast cancer spread in an orderly sequence: first through the breast, then through nearby tissues and lymph nodes, and finally to distant organs. Under this model, aggressive local surgery offered the best chance of stopping the disease before it escaped.

The operation became the dominant treatment for much of the twentieth century. It improved local control in an era with few alternatives, but it could also cause major disfigurement, arm swelling, weakness, chronic pain, and restricted shoulder movement. Later research showed that increasingly extensive surgery did not necessarily improve survival.

1895: The First Major Clue About Hormones

Scottish surgeon George Beatson reported that removing the ovaries caused regression of advanced breast cancer in some premenopausal patients. He did not know about estrogen receptors, but his observations demonstrated that at least some breast tumors depended on ovarian hormones.

This discovery planted the seed for endocrine therapy. Decades later, researchers would turn that biological clue into medications capable of blocking estrogen or reducing its production without automatically requiring ovarian surgery.

The Early 1900s: Radiation and Breast Imaging Arrive

1913: The Foundations of Mammography

German surgeon Albert Salomon used X-rays to study more than 3,000 mastectomy specimens. He showed that radiographic patterns could help distinguish cancerous growths from noncancerous tissue and could reveal small tumors and lymph-node involvement.

These images were not yet screening mammograms. They were studies of tissue that had already been removed. Nevertheless, Salomon’s work demonstrated that breast cancer could leave a detectable radiographic signature. Later improvements in film, compression, positioning, and radiation dose eventually made imaging living patients practical.

1930s–1960s: Mammography Becomes Clinically Useful

Radiologists gradually refined breast imaging during the mid-twentieth century. Dedicated mammography equipment and standardized techniques produced clearer images with lower radiation exposure. Screening studies in the 1960s and 1970s investigated whether mammography could find tumors before they became palpable.

By the 1980s, screening mammography had become a major component of breast cancer detection in the United States. It increased the diagnosis of small invasive cancers and ductal carcinoma in situ, while also creating enduring debates about screening ages, false-positive results, overdiagnosis, breast density, and equal access.

Radiation Therapy Develops Alongside Surgery

Doctors began experimenting with X-rays and radium soon after radiation was discovered. Early treatment could damage healthy tissue because physicians lacked precise planning systems and reliable dose measurements. Over time, radiation oncology developed safer machines, better targeting, and evidence-based treatment schedules.

Radiation ultimately became essential to breast-conserving therapy. Instead of trying to remove every potentially dangerous cell through a larger operation, surgeons could remove the visible tumor and radiation could treat microscopic disease remaining in the breast.

1940s–1980s: Breast Cancer Becomes a Systemic Disease

Chemotherapy Changes the Treatment Strategy

The development of anticancer drugs changed the central question from “How much tissue can be removed?” to “How can invisible cancer cells throughout the body be controlled?” Early chemotherapy regimens were difficult to tolerate, but clinical trials showed that drug treatment after surgery could reduce recurrence in selected patients.

Combination chemotherapy became particularly important because tumors could resist a single drug. Using medications with different mechanisms increased the chance of destroying cancer cells that had already traveled beyond the breast.

1960s–1970s: Bernard Fisher Challenges the Halsted Model

American surgeon and researcher Bernard Fisher argued that breast cancer could spread through the bloodstream relatively early. If distant microscopic disease was already present, removing additional chest tissue would not necessarily improve survival. Treatment needed to address both the breast and the rest of the body.

Trials conducted through the National Surgical Adjuvant Breast and Bowel Project compared radical mastectomy with less extensive operations. The results showed that removing more tissue did not automatically help patients live longer. This was one of oncology’s most important reversals: a treatment could be less physically destructive without being less medically effective.

1970s–1980s: Lumpectomy Plus Radiation

Clinical trials led by Fisher in the United States and Umberto Veronesi in Europe compared mastectomy with breast-conserving surgery followed by radiation for early breast cancer. Long-term findings demonstrated comparable survival for appropriately selected patients.

Breast-conserving therapy gradually became a standard option. The change was not merely cosmetic. It showed that randomized clinical evidence could overturn deeply rooted surgical tradition, even when that tradition had been taught for generations.

1977: Tamoxifen Is Approved

Tamoxifen was originally investigated for contraception, but researchers discovered that it could block estrogen activity in breast tissue. The FDA approved it for breast cancer treatment in 1977. It became a cornerstone of therapy for estrogen receptor-positive disease and was later used after surgery to reduce recurrence.

In 1998, results from the Breast Cancer Prevention Trial showed that tamoxifen could also substantially reduce breast cancer incidence among women at increased risk. The FDA subsequently approved it for risk reduction in eligible high-risk women.

The 1990s: Genetics and Targeted Therapy

1994–1995: BRCA1 and BRCA2 Are Identified

Researchers isolated BRCA1 in 1994 and BRCA2 in 1995 after studying families with unusually high rates of breast and ovarian cancer. Both genes normally help repair damaged DNA. Certain inherited variants can weaken that repair process and greatly increase cancer risk.

The discovery transformed genetic counseling, risk assessment, screening, preventive surgery, and treatment research. It also introduced complex questions about privacy, family communication, testing access, and what to do with knowledge of elevated risk. Having a genetic result, after all, is not the same as having an easy decision.

1998: Trastuzumab Targets HER2

Researchers had learned that some breast cancers produce excessive amounts of the HER2 protein, encouraging aggressive tumor growth. Trastuzumab, a monoclonal antibody designed to target HER2, received FDA approval in 1998 for HER2-overexpressing metastatic breast cancer.

This milestone helped establish the modern targeted-therapy model: test the tumor for a specific biological feature and prescribe a treatment directed at that feature. HER2-positive disease, once associated with a particularly difficult prognosis, became one of the clearest examples of how molecular classification could guide effective therapy.

The 2000s and 2010s: Treatment Becomes Personal

Genomic Tests Refine Chemotherapy Decisions

Gene-expression assays began helping clinicians estimate recurrence risk in certain early-stage breast cancers. Rather than recommending chemotherapy largely from tumor size and lymph-node status, physicians could incorporate molecular information into the discussion.

These tests did not eliminate uncertainty, but they helped many patients avoid chemotherapy when the expected benefit was small. They also reinforced a broader lesson: two tumors that look similar under a microscope may behave differently at the molecular level.

Sentinel Lymph-Node Biopsy Reduces Surgical Harm

Surgeons also adopted sentinel lymph-node biopsy, which examines the first node or small group of nodes most likely to receive drainage from a breast tumor. When those nodes are free of cancer, many patients can avoid a full axillary lymph-node dissection.

This change reduced the risk of lymphedema, numbness, pain, and shoulder problems while still supplying important staging information. Once again, progress meant doing lessbut doing it more intelligently.

2015–2017: CDK4/6 Inhibitors Enter Practice

The FDA approved palbociclib in 2015 for certain advanced hormone receptor-positive, HER2-negative breast cancers. Ribociclib and abemaciclib followed in 2017. These drugs inhibit proteins that help cancer cells progress through the cell-division cycle and are commonly combined with endocrine therapy.

CDK4/6 inhibitors became central treatments for advanced hormone receptor-positive disease and were later studied in earlier-stage settings. Their success illustrated how understanding the machinery of cell growth could produce treatments that delay progression without relying solely on conventional chemotherapy.

The 2020s: Immunotherapy and Antibody-Drug Conjugates

2021: Immunotherapy for High-Risk Early Triple-Negative Disease

Triple-negative breast cancer lacks estrogen receptors, progesterone receptors, and HER2 overexpression, leaving fewer traditional targets. In 2021, the FDA approved pembrolizumab with chemotherapy before surgery, followed by pembrolizumab after surgery, for patients with high-risk early-stage triple-negative breast cancer.

The approval brought immune-checkpoint therapy into curative-intent treatment for a breast cancer subtype known for aggressive behavior. It also demonstrated that treatment could begin before surgery not only to shrink a tumor, but to improve longer-term disease control.

2022–2025: The Meaning of HER2 Expands

Antibody-drug conjugates combine a targeted antibody with a cancer-killing payload. The antibody helps carry the drug toward cells displaying a particular marker, functioning somewhat like a delivery service whose package is decidedly unfriendly to the tumor.

In 2022, trastuzumab deruxtecan expanded treatment possibilities for metastatic cancers classified as HER2-low. In January 2025, the FDA broadened its use to certain hormone receptor-positive metastatic cancers described as HER2-low or HER2-ultralow after progression on endocrine therapy. These developments challenged the older idea that HER2 status fit neatly into only “positive” or “negative” boxes.

2026: Another Chapter, Not the Final Chapter

In May 2026, the FDA approved trastuzumab deruxtecan for two HER2-positive early-stage breast cancer indications, expanding the role of antibody-drug conjugates beyond metastatic disease. In June 2026, the agency also approved sacituzumab govitecan alone and with pembrolizumab for specified first-line triple-negative breast cancer settings.

These approvals show how quickly the timeline is moving. Breast cancer history is no longer measured only in centuries or decades. Meaningful changes can now occur within months as biomarker testing, drug engineering, and clinical-trial evidence reshape treatment pathways.

How the Breast Cancer Experience Has Changed

From One Standard Operation to a Menu of Decisions

For much of the twentieth century, a breast cancer diagnosis frequently led to one dominant recommendation: radical surgery. Patients had limited opportunity to compare treatment plans because the medical culture often treated the surgeon’s decision as final. Reconstruction was less available, emotional support was inconsistent, and the long-term effects of treatment received far less attention.

A person diagnosed today may instead meet a breast surgeon, medical oncologist, radiation oncologist, radiologist, pathologist, genetics professional, oncology nurse, reconstructive surgeon, and social worker. That multidisciplinary model can produce better-informed care, but it also creates a mountain of information. Tumor stage is only the beginning. Patients may hear about grade, margins, lymph nodes, estrogen receptors, progesterone receptors, HER2, Ki-67, inherited variants, genomic recurrence scores, chemotherapy, endocrine therapy, immunotherapy, and clinical trialssometimes before they have emotionally processed the word “cancer.”

The Emotional Experience Is Still Part of the History

Scientific progress does not make diagnosis emotionally tidy. Earlier generations often faced drastic surgery and silence. Modern patients may face a different burden: complicated choices with several medically reasonable options. Choosing between lumpectomy and mastectomy, deciding whether to pursue reconstruction, weighing chemotherapy benefit, or considering genetic testing can feel like being asked to take a final exam for a class nobody volunteered to attend.

The timeline also reveals why patient preferences matter. Equivalent survival does not mean every treatment feels equivalent. One person may prioritize breast preservation, while another may feel safer choosing mastectomy. Some want immediate reconstruction; others prefer a flat closure or delayed reconstruction. A sound decision reflects medical evidence as well as the patient’s health, values, risk tolerance, work, caregiving responsibilities, sexuality, body image, and access to follow-up care.

Survivorship Has Become a Major Phase of Care

As detection and treatment improved, more people began living for years or decades after breast cancer. That success produced new responsibilities. Survivorship care may involve monitoring for recurrence, managing early menopause, protecting bone and heart health, treating lymphedema, addressing fatigue or cognitive complaints, supporting sexual health, and coping with fear before scans and appointments.

History also warns against treating “survival” as the only outcome that matters. Halsted’s operation was judged largely by whether cancer returned near the surgical site. Modern care examines a wider picture: overall survival, distant recurrence, treatment toxicity, physical function, emotional well-being, fertility, financial strain, and quality of life. A therapy is not truly successful merely because it attacks the tumor. It should also preserve as much of the person’s life as possible.

Progress Has Not Reached Everyone Equally

The benefits of mammography, genetic counseling, specialized surgery, advanced drugs, and clinical trials depend on access. Insurance coverage, transportation, paid leave, geography, language, disability, medical mistrust, and the availability of oncology specialists can all shape the experience of care. A breakthrough medication cannot help someone who cannot obtain it, and an excellent screening recommendation has limited value when appointments are unavailable.

This is one of the most important lessons in the history of breast cancer: invention and delivery are different achievements. The next era must continue developing better treatments while making proven care easier to reach. Scientific progress deserves applause, but equitable access is what turns progress into public health.

What the Timeline Ultimately Teaches

The breast cancer timeline repeatedly rewards humility. Black bile was replaced by anatomy. Radical surgery was challenged by clinical trials. Tumors once grouped together were separated by hormone receptors, HER2 expression, inherited genes, and other molecular features. Categories such as HER2-negative were subdivided again when newer drugs proved capable of targeting lower levels of expression.

Future historians will probably find some of today’s assumptions incomplete, too. That is not a reason to distrust medicine; it is evidence of how medicine should work. Stronger research replaces weaker explanations, treatments are tested against one another, and recommendations change when better evidence appears.

The journey from an Egyptian physician writing “there is no treatment” to modern teams selecting therapies by tumor biology is extraordinary. Breast cancer has not been defeated, and metastatic disease remains a profound challenge. Yet the timeline demonstrates steady movement away from uniform, physically devastating treatment and toward earlier detection, more precise therapy, fewer unnecessary interventions, and greater respect for the person receiving care.